El 27 de abril de 2018 el Dr Jose Luis Mostaza Fernández (Jefe Servicio MI) analizó varios artículos del Lancet ID, son:

• Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
• Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram negative bacteria: an open label, randomised controlled trial. Trial AIDA.
• High dose tigecycline for the treatment of nosocomial carbapenem resistant Klebsiella pneumoniae bloodstream infections. A retrospective cohort study.
• The effects of antibiotic cycling and mixing on antibiotic resistance in intensive care units: a cluster randomised crossover trial.
• Discovery, research and development of new antibiotics: the WHO priority list of antibiotic resistant bacteria and tuberculosis.
• Extended pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open label, phase 3b/4 trial.

Su presentación se puede descargar aquí.